Brexit, the US-China trade war, Russia’s invasion of Ukraine—more such geopolitical surprises will continue the economic upheaval.
November 7, 2022 Issue
Features
Researchers are testing pricey infusions and cheap generics, but warn there’s likely no single solution.
Lowering birthrates is key to cutting poverty in the world’s most fertile population.
Less than 1% of used clothing gets recycled into new garments, overwhelming countries like Ghana with discards.
President Nayib Bukele tied his country’s fortunes to the digital token, but there isn’t much sign of it. Easier to find: Mass arrests and soldiers with machine guns.
A graphic look at the commodities that will underpin the transition to renewables.
Bloomberg Opinion
Punishing energy companies has become an easy way to supplement revenue, but such taxes carry significant risks.
Remarks
National security hawks muscle aside economists in setting policy direction.
Business
Their lucrative Yeezy collaboration accounted for more than an estimated 40% of the shoe giant’s profits. But the partners had been bickering for years.
Altering routes to avoid flying over the nation that invaded Ukraine can add hours—and extra fuel—to an already long journey.
Brian Savoy says power companies will use the fossil fuel as a bridge, while moving toward decarbonization.
Technology
The defining rivalry of the streaming-TV era began with an insult and a sneak attack. An exclusive adaptation from It’s Not TV: The Spectacular Rise, Revolution, and Future of HBO.
Finance
For years, Facebook, Amazon, Apple, Netflix and Google—the revered FAANG companies—were great investments. But a brutal quarter has revealed that they’re no longer sure things.
A retail boom that supercharged private equity and real estate is slowing, challenging one of the firm’s most ambitious efforts.
Economics
Brazil’s new leader wants to spend, but where will the money come from?
Democrats are pressing policymakers to minimize employment losses amid battle to restore price stability.
Tighter central bank policy is taking a toll on building activity and sales.
Solutions/Prognosis
Vertex is working on a drug that can quiet the body’s alarm system without leaving patients wanting more.
The company says people who have never had the disease can take its version—the issue that hobbled a rival effort from Sanofi.
William Parham says self-reflection can help workers across industries deal with emotional baggage.
